Answers are grounded in this paper and cite their sources.
Baseline data for response rate, clinical benefit ratio, duration of treatment, PFS, and OS were provided. Two subpopulations (relapsed/refractory) were clearly distinct and should be included in the interpretation of all trials. These results should help informing the design of forthcoming studies in relapsed/refractory neuroblastoma.
No takes yet. Share an insight, caveat, or question.
Moreno et al. (2016) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: